(Q28362588)

6 July 2017

0 references

Psychosis due to transdermally administered scopolamine (English)

1 reference

6 July 2017

1 reference

MacEwan GW

1

1 reference

6 July 2017

Remick RA

series ordinal

2

1 reference

6 July 2017

Noone JA

series ordinal

3

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 September 1985

1 reference

Canadian Medical Association Journal

6 July 2017

published in

1 reference

6 July 2017

volume

133

1 reference

6 July 2017

issue

5

1 reference

6 July 2017

page(s)

431-432

1 reference

Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs

6 July 2017

cites work

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1346539

Rate-controlled drug delivery

20 March 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1346539

Physostigmine salicylate as an antidote

29 September 2017

1 reference

12 December 2020

The anticholinergic intoxication syndrome: diagnosis and treatment

1 reference

12 December 2020

Transdermal scopolamine and toxic psychosis

1 reference

12 December 2020

Influence of sickle hemoglobinopathies on growth and development

1 reference

12 December 2020

Identifiers

PMC publication ID

1346539

1 reference

6 July 2017

1 reference